Company Overview

Sensus Healthcare, Inc. is a U.S.-based medical device company focused on non-invasive and minimally invasive treatments for oncological and dermatological conditions. The company develops and commercializes superficial radiotherapy (SRT) systems that use low-dose X-ray technology for the treatment of non-melanoma skin cancers, keloids, and other skin-related conditions. Sensus Healthcare operates within the healthcare technology and radiation oncology sectors, with its primary revenue generated from the sale, lease, and servicing of radiation therapy systems and related consumables. The company’s customer base includes dermatologists, radiation oncologists, hospital systems, and specialty treatment clinics.

The company is best known for its SRT-100, SRT-100 Vision, and SRT-100+ platforms, which are designed to deliver targeted superficial radiation therapy with image-guided capabilities. Sensus Healthcare positions itself as a provider of alternatives to surgical skin cancer treatments, particularly for patients seeking non-surgical options. Founded in 2010 and headquartered in Boca Raton, Florida, the company expanded through continued development of image-guided radiotherapy technologies and selective international distribution relationships. Public filings, including SEC filings, indicate that the company has emphasized operational efficiency and recurring service-related revenue alongside device sales.

Business Operations

Sensus Healthcare primarily operates through a single reportable business focused on the development, manufacturing, sale, and support of superficial radiotherapy systems. Revenue is generated from equipment sales, lease agreements, maintenance contracts, training, and service support. The company’s systems are designed for office-based and outpatient clinical settings, enabling dermatology and oncology providers to administer radiation treatments without the infrastructure requirements associated with larger linear accelerator systems. The company also markets accessories and software associated with its treatment platforms.

Operations are concentrated in the United States, though the company maintains international distribution relationships across parts of Europe, Asia, Latin America, and the Middle East. Sensus Healthcare controls proprietary technology related to low-energy radiation delivery and image-guided treatment workflows. The company has also pursued collaborations with physician practices and treatment providers to expand adoption of superficial radiotherapy. Public disclosures reference strategic efforts to support broader reimbursement acceptance and physician education related to non-invasive skin cancer treatment alternatives.

Strategic Position & Investments

Sensus Healthcare’s strategic direction has centered on expanding utilization of superficial radiotherapy for dermatologic oncology and broadening awareness among healthcare providers and payers. The company has invested in enhancing imaging capabilities and workflow integration within its treatment systems, particularly through the development of image-guided platforms such as SRT-100 Vision. Management has also emphasized recurring revenue opportunities through service contracts and long-term customer relationships.

In addition to dermatology-focused applications, Sensus Healthcare has explored broader oncology and specialty treatment opportunities, including technologies associated with low-dose radiation applications and adjunctive cancer care solutions. The company has disclosed initiatives related to expanding international distribution and evaluating complementary technologies within outpatient oncology care. Data regarding large-scale acquisitions or extensive subsidiary holdings remains limited in public filings, and some investment-related details are inconclusive based on available public sources.

Geographic Footprint

Sensus Healthcare is headquartered in Boca Raton, Florida, and derives a substantial portion of its revenue from the United States market. The company’s systems are used primarily in U.S.-based dermatology and radiation oncology practices, where non-melanoma skin cancer treatment represents a significant clinical focus. Domestic operations include manufacturing oversight, product development, sales management, and customer support functions.

Internationally, the company has established distribution arrangements spanning parts of Europe, Asia-Pacific, Latin America, and the Middle East. Public company disclosures indicate ongoing efforts to increase penetration in international markets where outpatient radiotherapy infrastructure and dermatologic oncology demand are expanding. While the company maintains a global commercial presence, its operational scale remains substantially smaller than major multinational radiation oncology equipment manufacturers.

Leadership & Governance

Sensus Healthcare was founded by industry executives with experience in radiation oncology technologies and outpatient treatment systems. The company’s leadership strategy has emphasized capital-efficient growth, physician-focused product development, and expansion of non-invasive treatment alternatives for skin cancer patients. Corporate governance is overseen by a board of directors and executive leadership team responsible for commercial operations, regulatory compliance, product development, and financial management.

Key executives identified in recent public disclosures include:

• Joe Sardano – Chairman and Chief Executive Officer
• Michael Sardano – President and General Counsel
• Jamey Schrier – Chief Financial Officer
• Pete Rivebark – Chief Operating Officer

Management communications in earnings materials and SEC filings consistently emphasize operational discipline, expansion of recurring revenue streams, and continued adoption of image-guided superficial radiotherapy technologies within dermatology and oncology practices.